| Cat. No. |
Product Name & Pharmacological Action |
| 0101 | DL-AP4 |
| Broad spectrum EAA antagonist |
| 0102 | D-AP4 |
| Weak, non-selective NMDA antagonist |
| 0103 | L-AP4 |
| Agonist; also group III mGlu agonist |
| 0104 | DL-AP7 |
| Specific NMDA antagonist |
| 0105 | DL-AP5 |
| Potent, selective NMDA antagonist |
| 0106 | D-AP5 |
| More active form of DL-AP5 (0105) |
| 0107 | L-AP5 |
| Less active form of DL-AP5 (0105) |
| 0109 | (-)-Bicuculline methobromide |
| Water-soluble GABAA antagonist |
| 0111 | Dihydrokainic acid |
| EAAT2 (GLT-1)-selective non-transportable inhibitor of L-glutamate and L-aspartate uptake |
| 0112 | γDGG |
| 'Broad spectrum' glutamate receptor antagonist |
| 0114 | NMDA |
| Selective NMDA agonist |
| 0125 | DL-AP3 |
| Group I mGlu antagonist |
| 0130 | (+)-Bicuculline |
| Potent GABAA antagonist |
| 0131 | (-)-Bicuculline methochloride |
| Water-soluble GABAA antagonist |
| 0162 | S-Sulfo-L-cysteine sodium salt |
| Group I agonist |
| 0164 | D-AP7 |
| More active form of DL-AP7 (0104) |
| 0169 | (RS)-AMPA |
| Selective AMPA agonist |
| 0173 | (RS)-CPP |
| Potent NMDA antagonist |
| 0178 | Phaclofen |
| Weak, selective GABAB antagonist |
| 0180 | ZAPA sulfate |
| Agonist at 'low affinity' GABAA receptor. More potent than GABA/muscimol |
| 0181 | TACA |
| GABAA agonist. Also GABA-T substrate and GABA uptake inhibitor |
| 0183 | L-(-)-threo-3-Hydroxyaspartic acid |
| Transportable EAAT1-4 inhibitor/non-transportable EAAT5 inhibitor |
| 0186 | cis-ACPD |
| Potent NMDA agonist |
| 0187 | (±)-trans-ACPD |
| Group I/group II mGlu agonist |
| 0188 | L-Quisqualic acid |
| AMPA/group I mGlu agonist |
| 0189 | DNQX |
| Selective non-NMDA antagonist |
| 0190 | CNQX |
| Potent AMPA/kainate antagonist |
| 0197 | Homoquinolinic acid |
| Selective, potent NMDA agonist |
| 0204 | D-Alanine |
| Weak glycine receptor agonist |
| 0205 | L-Alanine |
| Glycine receptor agonist, more potent than D-isomer (0204) |
| 0206 | β-Alanine |
| Endogenous glycine agonist, more selective than Taurine (Cat. No. 0209) |
| 0208 | Hypotaurine |
| Non-selective endogenous glycine receptor agonist |
| 0209 | Taurine |
| Non-selective, endogenous glycine receptor partial agonist |
| 0213 | D-Aspartic acid |
| NMDA agonist |
| 0214 | L-Aspartic acid |
| NMDA agonist |
| 0216 | L-Cysteinesulfinic acid |
| NMDA and mGlu agonist |
| 0217 | D-Glutamic acid |
| NMDA agonist, less active enantiomer |
| 0218 | L-Glutamic acid |
| Endogenous NMDA agonist |
| 0219 | Glycine |
| Endogenous potentiator, co-transmitter |
| 0222 | Kainic acid |
| Potent excitant and neurotoxin |
| 0223 | Kynurenic acid |
| Broad spectrum EAA antagonist |
| 0225 | Quinolinic acid |
| Transmitter candidate |
| 0226 | D-Serine |
| Potentiator, acts glycine site |
| 0227 | L-Serine |
| Weak endogenous glycine receptor agonist |
| 0234 | Guvacine hydrochloride |
| Specific GABA uptake inhibitor |
| 0235 | Isoguvacine hydrochloride |
| Selective GABAA agonist |
| 0236 | (±)-Nipecotic acid |
| GABA uptake inhibitor |
| 0237 | 7-Chlorokynurenic acid |
| Potent, competitive inhibitor of L-glutamate uptake |
| 0238 | O-Phospho-L-serine |
| Group III mGlu agonist |
| 0245 | 2-Hydroxysaclofen |
| Selective GABAB antagonist, more potent than saclofen (Cat. No. 0246) |
| 0246 | Saclofen |
| Selective GABAB antagonist |
| 0247 | (R)-CPP |
| More active enantiomer |
| 0253 | (R)-AMPA |
| Inactive isomer of (RS)-AMPA (0169) |
| 0254 | (S)-AMPA |
| Selective AMPA agonist. Active isomer |
| 0258 | ACBC |
| NMDA antagonist, acts glycine site |
| 0262 | 2,4-Dihydroxyphenylacetyl-L-asparagine |
| Component of Joro spider toxin |
| 0269 | Domoic acid |
| Potent, selective kainate agonist |
| 0270 | trans-ACBD |
| Selective, very potent NMDA agonist |
| 0271 | cis-ACBD |
| Potent, selective L-glutamate uptake inhibitor |
| 0281 | (R)-(+)-HA-966 |
| Partial NMDA agonist, acts glycine site |
| 0282 | (S)-(-)-HA-966 |
| NMDA antagonist/partial agonist |
| 0284 | (1S,3R)-ACPD |
| Group I/group II mGlu agonist |
| 0285 | Ibotenic acid |
| Non-selective NMDA agonist |
| 0286 | 5,7-Dichlorokynurenic acid |
| Potent NMDA antagonist, acts glycine site |
| 0289 | Muscimol |
| Potent GABAA agonist |
| 0290 | N-(4-Hydroxyphenylacetyl)spermine |
| Wasp toxin analogue |
| 0291 | N-(4-Hydroxyphenylpropanoyl) spermine trihydrochloride |
| Non-selective EAA antagonist |
| 0298 | L-trans-2,4-PDC |
| Transportable EAAT1-4 inhibitor/non-transportable EAAT5 inhibitor |
| 0306 | (S)-(-)-5-Fluorowillardiine |
| Very potent AMPA agonist |
| 0307 | (S)-(-)-5-Iodowillardiine |
| Highly potent, subtype selective kainate agonist |
| 0310 | (RS)-4-Carboxy-3-hydroxyphenylglycine |
| 'Broad spectrum' EAA ligand |
| 0312 | (RS)-(Tetrazol-5-yl)glycine |
| Highly potent NMDA receptor agonist |
| 0320 | (S)-4-Carboxy-3-hydroxyphenylglycine |
| Group I antagonist/group II agonist |
| 0321 | (RS)-4-Carboxyphenylglycine |
| 'Broad spectrum' EAA ligand |
| 0322 | (R)-4-Carboxyphenylglycine |
| Moderately potent NMDA antagonist |
| 0323 | (S)-4-Carboxyphenylglycine |
| Competitive group I mGlu antagonist/weak group II agonist |
| 0324 | (RS)-3-Hydroxyphenylglycine |
| Group I mGlu agonist |
| 0326 | (S)-3-Hydroxyphenylglycine |
| Group I mGlu agonist, active isomer |
| 0328 | (R)-3-Carboxy-4-hydroxyphenylglycine |
| Moderately potent NMDA antagonist |
| 0329 | (S)-3-Carboxy-4-hydroxyphenylglycine |
| Group I antagonist/group II agonist |
| 0332 | L-CCG-lll |
| Potent, competitive uptake inhibitor |
| 0333 | L-CCG-l |
| Potent group II mGlu agonist |
| 0336 | (RS)-MCPG |
| Non-selective mGlu antagonist |
| 0337 | (S)-MCPG |
| Active isomer of Cat. No. 0336 |
| 0341 | L-AP6 |
| Selective agonist, highly potent |
| 0342 | (RS)-3,5-DHPG |
| Selective group I mGlu agonist |
| 0344 | GABA |
| Endogenous agonist |
| 0347 | nor-Binaltorphimine dihydrochloride |
| Standard κ selective antagonist |
| 0348 | 2-BFI hydrochloride |
| Potent, selective I2 ligand. Putative agonist |
| 0351 | 1-Acetyl-4-methylpiperazine hydrochloride |
| Nicotinic agonist
|
| 0352 | 4-Acetyl-1,1-dimethylpiperazinium iodide |
| Nicotinic agonist
|
| 0355 | (±)-Acetylcarnitine chloride |
| Intermediate in lipid metabolism |
| 0357 | N-Acetyltryptamine |
| Melatonin partial agonist (MT1/MT2). Also MT3 antagonist |
| 0360 | (±)-1-(1,2-Diphenylethyl)piperidine maleate |
| NMDA antagonist, acts ion channel site |
| 0361 | W-13 hydrochloride |
| Calmodulin antagonist |
| 0366 | A-3 hydrochloride |
| Protein kinase inhibitor |
| 0368 | W-5 hydrochloride |
| Calmodulin antagonist |
| 0369 | W-7 hydrochloride |
| Calmodulin antagonist. Inhibits myosin light chain kinase |
| 0370 | W-9 hydrochloride |
| Calmodulin antagonist |
| 0373 | NBQX |
| Potent AMPA/kainate antagonist, more selective than CNQX (Cat. No. 0190) |
| 0378 | A-7 hydrochloride |
| Calmodulin antagonist |
| 0379 | SKF 97541 |
| Extremely potent GABAB agonist |
| 0380 | Y-25130 hydrochloride |
| Potent, selective 5-HT3 antagonist |
| 0382 | Arecaidine but-2-ynyl ester tosylate |
| Muscarinic agonist |
| 0383 | Arecaidine propargyl ester tosylate |
| Muscarinic agonist
|
| 0384 | N-Acetyl-L-leucyl-L-leucyl-L-methional |
| Cathepsin inhibitor |
| 0385 | SG 209 |
| K+ channel opener |
| 0386 | 3-Methyl-GABA (2:1 salt with naphthalene-1,5-disulfonic acid) |
| Activator of GABA amino-transferase |
| 0387 | (RS)-Atenolol |
| β1 antagonist
|
| 0388 | Ambenonium dichloride |
| Cholinesterase inhibitor
|
| 0389 | Arcaine sulfate |
| Competitive NMDA antagonist |
| 0391 | Spaglumic acid |
| Selective mGlu3 agonist |
| 0393 | S-(-)-Atenolol |
| Active isomer
|
| 0395 | N-Acetylglycyl-D-glutamic acid |
| Potent convulsant |
| 0396 | H-9 dihydrochloride |
| Protein kinase inhibitor |
| 0405 | β-CCB |
| Benzodiazepine inverse agonist, putative endogenous ligand |
| 0411 | MDL 73005EF hydrochloride |
| Potent and selective 5-HT1A partial agonist |
| 0412 | MDL 72832 hydrochloride |
| Potent 5-HT1A ligand |
| 0414 | AG 490 |
| EGFR-kinase inhibitor. Also Jak2, Jak3 inhibitor |
| 0415 | Ro 20-1724 |
| PDE4 inhibitor |
| 0416 | YS-035 hydrochloride |
| Inhibits K+ outward/pacemaker current |
| 0417 | (RS)-Baclofen |
| Selective GABAB agonist |
| 0420 | GBR 13069 dihydrochloride |
| Potent dopamine uptake inhibitor
|
| 0421 | GBR 12909 dihydrochloride |
| Selective DA uptake inhibitor. Also σ ligand
|
| 0424 | Benzoquinonium dibromide |
| Nicotinic antagonist |
| 0425 | UK 14,304 |
| α2 agonist
|
| 0426 | L-693,403 maleate |
| High affinity σ ligand |
| 0427 | Bromocriptine mesylate |
| Selective D2-like agonist
|
| 0430 | SC-10 |
| Protein kinase C activator |
| 0431 | ML 9 hydrochloride |
| Myosin light chain kinase inhibitor |
| 0432 | MY-5445 |
| PDE5 inhibitor |
| 0433 | SC-9 |
| Protein kinase C activator |
| 0435 | Cimaterol |
| β agonist |
| 0438 | Etazolate hydrochloride |
| PDE4 inhibitor |
| 0439 | DPCPX |
| A1 selective antagonist |
| 0440 | m-Chlorophenylbiguanide hydrochloride |
| Potent and specific 5-HT3 agonist |
| 0442 | 4-Chlorophenylguanidine hydrochloride |
| Urokinase inhibitor |
| 0443 | 6-Chloromelatonin |
| Melatonin agonist |
| 0444 | Clozapine |
| Dopamine antagonist with some D4 selectivity. Also muscarinic antagonist and 5-HT ligand |
| 0448 | Calpeptin |
| Calpain and cathepsin L inhibitor |
| 0452 | CCCP |
| Oxidative phosphorylation uncoupler |
| 0453 | FCCP |
| Oxidative phosphorylation uncoupler |
| 0454 | Carbetapentane citrate |
| High affinity σ1 ligand |
| 0455 | (S)-(-)-Carbidopa |
| Aromatic L-amino acid decarboxylase inhibitor |
| 0456 | Chlormezanone |
| Skeletal muscle relaxant |
| 0457 | Clomipramine hydrochloride |
| 5-HT re-uptake inhibitor |
| 0458 | 5-Carboxamidotryptamine maleate |
| 5-HT1 agonist. Also has high affinity for 5-ht5A and 5-HT7 |
| 0460 | Cinanserin hydrochloride |
| Selective 5-HT2 antagonist |
| 0462 | (E)-Capsaicin |
| Prototypic vanilloid receptor agonist |
| 0463 | (Z)-Capsaicin |
| Cis isomer of (E)-Capsaicin (0462) |
| 0464 | Capsazepine |
| Vanilloid receptor antagonist. Also activator of ENaCδ |
| 0468 | N1,N11-Diethylnorspermine tetrahydrochloride |
| Spermine and spermidine acetyltransferase potentiator |
| 0469 | Nitrocaramiphen hydrochloride |
| Muscarinic antagonist, M1 > M2
|
| 0471 | (+)-U-50488 hydrochloride |
| Less active enantiomer of Cat. No. 0495 |
| 0474 | Dihydroergocristine mesylate |
| Partial α agonist. Non selective
|
| 0475 | Dihydroergotamine mesylate |
| Partial α agonist. Non selective
|
| 0476 | 2,4-Diamino-6-hydroxypyrimidine |
| Inhibits biosynthesis of tetrahydrobiopterin and thus NOS |
| 0477 | (±)-Decanoylcarnitine chloride |
| Intermediate in lipid metabolism |
| 0478 | Flurofamide |
| Urease inhibitor |
| 0479 | Malonoben |
| Oxidative phosphorylation uncoupler |
| 0481 | Dilazep dihydrochloride |
| Adenosine uptake inhibitor |
| 0482 | 4-DAMP |
| Muscarinic M3 antagonist
|
| 0483 | OR-486 |
| Catechol-O-methyl transferase inhibitor |
| 0484 | Dioctanoylglycol |
| Diacylglycerol kinase inhibitor |
| 0485 | Alrestatin |
| Aldose reductase inhibitor |
| 0486 | 1,3-Dipropyl-8-phenylxanthine |
| A1 selective antagonist |
| 0493 | AG 18 |
| EGFR/PDGFR-kinase inhibitor |
| 0495 | (±)-U-50488 hydrochloride |
| Standard selective κ agonist |
| 0496 | (-)-U-50488 hydrochloride |
| More active enantiomer of Cat. No. 0495 |
| 0497 | AG 99 |
| EGFR-kinase inhibitor |
| 0498 | U-54494A hydrochloride |
| κ agonist |
| 0500 | N1,N12-Diethylspermine tetrahydrochloride |
| Polyamine synthase inhibitor |
| 0503 | AG 213 |
| EGFR/PDGFR-kinase inhibitor |
| 0504 | Diphenyleneiodonium chloride |
| Binds to flavoproteins and inhibits NOS |
| 0505 | Dihydroergotoxine mesylate |
| Binds with high affinity to GABAA receptor Cl- channel |
| 0506 | Dimaprit dihydrochloride |
| Standard H2 selective agonist |
| 0507 | Dantrolene, sodium salt |
| Ca2+ release inhibitor |
| 0508 | Doxepin hydrochloride |
| Highly potent H1 antagonist. Also binds to H4 receptor |
| 0511 | BD 1008 dihydrobromide |
| Potent, selective σ ligand |
| 0512 | SKF 91488 dihydrochloride |
| Histamine N-methyltransferase inhibitor |
| 0513 | GBR 12783 dihydrochloride |
| Potent, selective dopamine uptake inhibitor
|
| 0514 | GBR 12935 dihydrochloride |
| Selective dopamine uptake inhibitor
|
| 0515 | Dobutamine hydrochloride |
| β1 and β2 agonist. Also α1 agonist
|
| 0516 | Etonitazenyl isothiocyanate |
| Irreversible affinity label (µ selective) |
| 0518 | EBPC |
| Aldose reductase inhibitor |
| 0522 | Flunarizine dihydrochloride |
| Dual Na+/Ca2+ channel (T-type) blocker |
| 0523 | 4F 4PP oxalate |
| Selective 5-HT2 antagonist |
| 0524 | AMI-193 |
| D2-like receptor antagonist |
| 0526 | (±)-Hexanoylcarnitine chloride |
| Intermediate in lipid metabolism |
| 0529 | 8-Hydroxy-DPAT hydrobromide |
| Selective 5-HT1A agonist. Also has moderate affinity for 5-HT7 |
| 0532 | W-84 dibromide |
| Antagonist-receptor complex stabiliser
|
| 0535 | HEAT hydrochloride |
| Highly selective α1 antagonist |
| 0537 | MR 16728 hydrochloride |
| Stimulates ACh release
|
| 0538 | trans-4-Hydroxycrotonic acid |
| GHB receptor ligand |
| 0541 | Fasudil hydrochloride |
| Inhibitor of cyclic nucleotide dependent- and Rho-kinases |
| 0542 | H-7 dihydrochloride |
| Protein kinase inhibitor |
| 0543 | C-1 |
| Protein kinase C inhibitor |
| 0544 | IPAG |
| Potent σ antagonist |
| 0545 | Ifenprodil hemitartrate |
| Non-competitive NMDA antagonist. Also σ ligand |
| 0546 | L-NIO dihydrochloride |
| Potent eNOS inhibitor |
| 0548 | (±)-Lauroylcarnitine chloride |
| Intermediate in lipid metabolism |
| 0549 | Methylergometrine maleate |
| Active metabolite of methysergide |
| 0552 | MMPX |
| PDE1 inhibitor |
| 0553 | NAN-190 hydrobromide |
| 5-HT1A antagonist |
| 0554 | FG 7142 |
| Benzodiazepine inverse agonist |
| 0556 | BP 554 maleate |
| Selective 5-HT1A agonist |
| 0557 | α-Methyl-5-hydroxytryptamine maleate |
| 5-HT2 agonist |
| 0558 | 2-Methyl-5-hydroxytryptamine hydrochloride |
| 5-HT3 agonist/potent 5-ht6 ligand |
| 0566 | N-Methylquipazine dimaleate |
| 5-HT3 agonist |
| 0567 | (±)-Myristoylcarnitine chloride |
| Intermediate in lipid metabolism |
| 0568 | Metaphit |
| Acylator of PCP and σ receptors |
| 0569 | (R)-(-)-α-Methylhistamine dihydrobromide |
| Potent, standard H3 agonist |
| 0571 | PCA 4248 |
| PAF receptor antagonist |
| 0572 | (S)-(+)-α-Methylhistamine dihydrobromide |
| H3 agonist, less active enantiomer |
| 0573 | Nα-Methylhistamine dihydrochloride |
| Non-selective H3 agonist |
| 0577 | Methyl 2,5-dihydroxycinnamate |
| EGFR-kinase inhibitor |
| 0578 | Tyrphostin B44, (-) enantiomer |
| EGFR-kinase inhibitor |
| 0579 | Tyrphostin B44, (+) enantiomer |
| EGFR-kinase inhibitor |
| 0581 | 3-[2-[4-(2-Methoxyphenyl)piperazin-1-yl] ethyl]pyrimido[5,4-b] indole-2,4-dione |
| α1 ligand
|
| 0582 | Methiothepin maleate |
| Has moderate affinity for 5-ht5 and high affinity for 5-ht6 and 5-HT7. Also antagonist at 5-HT1 and 5-HT2 |
| 0583 | Minoxidil |
| K+ channel (KATP) opener |
| 0584 | L-(-)-α-Methyldopa |
| Aromatic L-amino acid decarboxylase inhibitor |
| 0588 | 5-Methylfurmethiodide |
| Potent muscarinic agonist
|
| 0589 | PRE-084 hydrochloride |
| Highly selective σ1 agonist |
| 0590 | Metergoline |
| 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-ht6 and high affinity for 5-HT7 |
| 0591 | Naloxonazine dihydrochloride |
| Selective µ1 antagonist |
| 0593 | NPPB |
| Chloride channel blocker |
| 0597 | Naftopidil hydrochloride |
| α1 antagonist |
| 0598 | SNAP |
| A stable analogue of endogenous S-nitroso compounds |
| 0599 | Naloxone hydrochloride |
| Broad spectrum opioid antagonist |
| 0600 | Nimodipine |
| Ca2+ channel blocker (L-type) |
| 0601 | Nitrendipine |
| Ca2+ channel blocker (L-type) |
| 0602 | 7-Nitroindazole |
| Non-selective NOS inhibitor |
| 0603 | SNOG |
| NO carrier. Breaks down to release NO |
| 0604 | Nicergoline |
| α antagonist
|
| 0605 | (±)-Octanoylcarnitine chloride |
| Intermediate in lipid metabolism |
| 0606 | OBAA |
| Phospholipase A2 inhibitor |
| 0607 | 17-ODYA |
| LTB-ω-Hydroxylase inhibitor |
| 0609 | (±)-Palmitoylcarnitine chloride |
| Protein kinase C inhibitor |
| 0610 | Parthenolide |
| 5-HT release inhibitor |
| 0611 | |